Genicore is translating Genimer™ technology into a global standard, scaling aptamers from high-end labs into industrial-grade, large-scale deployment. By overcoming traditional antibody limits—such as animal dependency, high costs, and batch inconsistency—our standardized framework delivers superior performance at a fraction of the cost, making precision biological tools the bedrock infrastructure for global healthcare.

In biomedical R&D, time is the ultimate cost. Genicore utilizes AI molecular simulation and automated SELEX to slash ligand development timelines from months to mere weeks. By adopting a "digital twin" approach—screening in-silico before lab validation—we exponentially boost success rates and fast-track tools for emerging diseases and rare drug pipelines.

Driven by absolute specificity and sensitivity, Genicore leverages the small size and superior permeability of Genimer™ to detect micro-signals beyond the reach of traditional antibodies. By eliminating background interference, we deliver artifact-free biological data—establishing a robust foundation for early cancer detection, liquid biopsy, and tailor-made personalized healthcare.

Anchored in Taiwan with a global footprint, Genicore is pioneering a green biotech revolution. By utilizing chemical synthesis for aptamer production, we eliminate laboratory animal testing to meet modern ESG benchmarks. Over the next five years, we aim to forge a complete global value chain across diagnostics, therapeutics, and research—shaping a more precise, humane, and sustainable future for healthcare.